Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation

Recruiting N/A Interventional Study
Treatment Resistant Schizophrenia
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
20 (estimated)
Sponsor
Centre Hospitalier St Anne · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected individuals. One third of patients suffering from schizophrenia will evolve towards a resistant form of the disease, amongst which many will suffer from auditory-verbal halluc…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age \> 18 years old * Schizophrenic Disorder (Diagnostic and statistical manual of mental disorders, DSM-5-TR, American Psychiatric Association, 2013) * AVHs that have resisted to at least two properly conducted antipsychotic therapies at an effective dose for at least 8 weeks…
Contacts

Philippe Domenech, MD, PhD

(0)1 49 81 22 01

philippe.domenech@ghu-paris.fr

CONTACT

Fabien Vinckier, MD, PhD

(0) 1 45 65 84 52

f.vinckier@ghu-paris.fr

CONTACT